Search Result

Results for "

OICR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (1) Bcl-2 Family (2) BCL6 (1) E3 Ligase Ligand-Linker Conjugates (1) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (2) MARK (1) PROTACs (1) WDR5 (6) YAP (1)
By Research Areas:	Cancer (12) Infection (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16993

OICR-9429 10+ Cited Publications	Apoptosis WDR5	Cancer
OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .

HY-141799

*Dimethyl-F-OICR-9429-COOH*	Ligands for Target Protein for PROTAC WDR5	Cancer
Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs .

HY-149935

OICR-8268	Ligands for E3 Ligase	Cancer
OICR-8268 is a reversible DCAF1 ligand that binds to the DCAF1 WDR domain with a K_d of 38 nM. OICR-8268 can enable the development of DCAF1-based PROTACs .

HY-154949

WDR5-IN-6	WDR5	Cancer
WDR5-IN-6 is a WDR5 inhibitor, targeting to WBM site. WDR5-IN-6 inhibits cell proliferation of neuroblastoma cell lines with potent anti-tumor activity. WDR5-IN-6 shows high synergy with OICR-9429 (HY-16993), a WDR5 inhibitor targeting to WIN site. WDR5-IN-6 can be used for reasearch in neuroblastoma .

HY-16994

OICR-0547	WDR5	Cancer
OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .

HY-175343

OICR-41103	Ligands for E3 Ligase	Infection
OICR-41103 is an effective, selective, cell-active DCAF1 small molecule chemical probe that targets the DCAF1 WDR domain and replaces the viral Vpr protein. The binding K_i value of OICR-41103 and DCAF1 is less than 2 nM .

HY-141798

OICR-9429-N-C2-NH2	Ligands for Target Protein for PROTAC WDR5	Cancer
OICR-9429-N-C2-NH2 is a ligand for Wd40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs .

HY-169390

OICR-8268-acrylic acid	Ligands for E3 Ligase	Cancer
OICR-8268-acrylic acid is a ligand for E3 ubiquitin ligase. OICR-8268-acrylic acid can be connected to the ligand for protein by a linker to form OICR41114 (HY-169389). OICR41114 can be used in anti-cancer research .

HY-175343A

OICR-41103N	Ligands for E3 Ligase	Infection
OICR-41103N is the negative control form of OICR-41103 (HY-175343). OICR-41103 is an effective, selective, cell-active DCAF1 small molecule chemical probe (K_i<2 nM) that targets the DCAF1 WDR domain and replaces the viral Vpr protein .

HY-169389

OICR41114	PROTACs WDR5	Cancer
OICR41114 is a WDR5 PROTAC degrader with an EC₅₀ of 40 nM. OICR41114 binds both DCAF1 and WDR5, and its binding affinity for DCAF1 is significantly enhanced in the presence of WDR5 (K_D increases from 59 nM to 5 nM). OICR41114 exerts antiproliferative effects on MV4-11 cells. OICR41114 can be used for the research of acute myeloid leukemia .

HY-168907

OICR11029	BCL6	Others
OICR11029 is a highly efficient probe for Bcl-6 .

HY-153096

OICR12694 JNJ-65234637	Bcl-2 Family	Cancer
OICR12694 (JNJ-65234637) is an orally active inhibitor of B cell lymphoma 6 (BCL6) .

HY-153096A

OICR12694 TFA JNJ-65234637 TFA	Bcl-2 Family	Cancer
OICR12694 (JNJ-65234637) TFA is an orally active inhibitor of B cell lymphoma 6 (BCL6) .

HY-169391

OICR-8268-acrylic acid-amino-PEG9-amine	E3 Ligase Ligand-Linker Conjugates	Cancer
OICR-8268-acrylic acid-amino-PEG9-amine is an E3 ligase ligand-linker conjugate. OICR-8268-acrylic acid-amino-PEG9-amine can be used to synthesize OICR41114 (HY-169389) .

HY-182743

OICR19451	AMPK MARK YAP	Cancer
OICR19451 is an orally active dual NUAK1/NUAK2 and MARK2/MARK3 kinase inhibitor, with IC₅₀ values of 12 nM and 10 nM against NUAK1 and NUAK2, and 101 nM and 124 nM against MARK2 and MARK3, respectively. OICR19451 modulates the Hippo signaling pathway, increases the phosphorylation level of YAP, enhances the cytoplasmic localization of YAP/TAZ, and inhibits the expression of oncogenes. OICR19451 inhibits cancer cell growth, reduces metastasis, promotes tumor capsule formation, and improves mouse survival in an orthotopic breast cancer model. OICR19451 can be used for research related to triple-negative breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

OICR

Inhibitors & Agonists